Development and evaluation of pneumococcal conjugate vaccines: Clinical trials and control tests

Critical Reviews in Microbiology

Volumn 28, Issue 1, 2002, Pages 27-41

  Lee, Lucia H ^a   Lee, Chi Jen ^a   Frasch, Carl E ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Carriage; Efficacy; Pneumococcus; Quality control; Vaccine

Indexed keywords

CARRIER PROTEIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PENICILLIN G; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; CLINICAL TRIAL; DRUG APPROVAL; DRUG CONJUGATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; OTITIS MEDIA; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINE PRODUCTION; WORLD HEALTH ORGANIZATION;

HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS INFLUENZAE SEROTYPE B; POSIBACTERIA; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0036211538     PISSN: 1040841X     EISSN: None     Source Type: Journal    
DOI: 10.1080/1040-840291046678     Document Type: Review

References (100)

1. Prevention of pneumococcal disease: Recommendation of the advisory committee on immunization practices (ACIP)
2. Ten-year review of otitis media pathogens
3. Clinical and epidemiologic studies of pneumococcal infection in children
4. Epidemiology of otitis media during the first years of life in children in greater Boston: A prospective, cohort study
5. Streptococcus pneumoniae
6. Increasing prevalence of multidrug-resistant streptococcus pneumoniae in the United States
7. Clinical isolates of Streptococcus pneumoniae that exhibit tolerance of vancomycin
8. The continued emergence of drug-resistant streptococcal pneumonia in the United States: An update from the CDC's Pneumococcal Sentinel Surveillance System
9. Emergence of drug-resistant infections in the United States
10. Drug-resistant pneumococcal infections in the United States: A problem for clinicians, laboratories, and public health
11. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae
12. Pneumococcal vaccine
13. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people
14. Pneumococcal conjugate vaccines in pharmaceutical biotechnology
15. Six newly recognized types of Streptococcus pneumoniae
16. Pneumococcal polysaccharide vaccines
17. Consideration for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types
18. Virulence, immunity, and vaccine related to Streptococcus pneumoniae
19. Advances in pneumococcal vaccines
20. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations
21. The clinical effectiveness of pneumococcal vaccine in the elderly
22. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
23. Antibody response to pneumococcal vaccination in children younger than five years of age
24. Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in preschool age children
25. Characteristics of immune responses to native and protein conjugated pneumococcal polysaccharide type 14
26. Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines
27. New challenges in the development of a conjugate pneumococcal vaccine
28. Immune responses of young mice to pneumococcal type 9V polysaccharide-tetanus toxoid conjugate
29. Protection of infant mice from challenge with Streptococcus pneumoniae type 19F by immunization with a type 19F polysaccharide-pneumolysin conjugate
30. Purification and immunogenicity of genetically toxoided derivatives of pneumolysin and their conjugation to Streptococcus pneumoniae type 19F polysaccharide
31. Decline of childhood Haemophilus influenzae type b disease in the Hib vaccine era
32. Decline incidence of Haemophilus influenzae type b disease since introduction of vaccination
33. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants
34. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine
35. Pneumococcal vaccines for children: An update
36. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children
37. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children
38. Immunologic memory in young infants induced by a pneumococcal conjugate vaccine
39. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants
40. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well tolerated and able to induce an antibody response in infants
41. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid
42. Conjugate vaccine against Streptococcus pneumoniae
43. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants
44. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine
45. Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines
46. Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: Comparison with human anti-polysaccharide 23F IgG
47. Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin
48. The direct coupling of oligosaccharides to proteins and derivatized gels
49. Proteins containing reductively aminated disaccharides: Synthesis and chemical characterization
50. Immunogenicity in mice of pneumococcal glycoconjugate vaccines using pneumococcal protein carriers
51. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in proteinpolysaccharide conjugate vaccines and immunological reagents
52. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide protein conjugates
53. Efficacy of pneumococcal conjugate vaccine against acute otitis media
54. Nasopharyngeal (NP) carriage of Streptococcal pneumoniae (Pnc) in toddlers vaccinated during infancy with an 11 valent pneumococcal vaccine conjugated to diphtheria and tetanus toxoids (PCV-DT)
55. Antibody (Ab) response to an 11-valent pneumococcal (Pnc) conjugate vaccine in Filipino, Finnish and Israeli infants
56. An eleven-valent pneumococcal conjugate vaccine is able to induce tetanus and diphtheria antitoxin responses in healthy adults and toddlers
57. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
58. Efficacy of a seven valent pneumococcal conjugate vaccine in high risk american indian population
59. Potential interventions for the prevention of childhood pneumonia: Geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children - Implications for vaccine strategies
60. Safety and immunogenicity of a single injection of a 9-valent pneumococcal conjugate vaccine mixed with DTP-Hib (Tetramune®) in Gambian infants
61. Nine-valent conjugate pneumococcal vaccine trial in Soweto, South Africa
62. Epidemiology of pneumococcal serotypes and conjugate vaccine formulations
63. Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I
64. The contribution of specific pneumococcal serogroups to different disease manifestations: Implications for conjugate vaccine formulation and use, part II
65. Reduction of nasopharyngeal (NP) carriage in day care center (DCC) attendees after vaccination with a 9-valent CRM197 conjugate pneumococcal vaccine (PncCRM197)-protection against individual serotypes
66. Immunization of toddlers attending day care centers (DCCs) with a 9-valent conjugate pneumococcal vaccine (PncCRM9) reduces transmission of Streptococcus pneumoniae (Pnc) and antibiotic resistant S. pneumoniae (R-Pnc) to their young siblings (YS)
67. 197 conjugate vaccine in infants and toddlers
68. Pneumococcal vaccine
69. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine
70. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine
71. Carriage of pneumococci after pneumococcal vaccination
72. Bacterial vaccines and serotype replacement: Lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae
73. Development and validation of an NMR-based identity assay for bacterial polysaccharides
74. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells
75. An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study
76. Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization
77. Virulence, immunity and vaccine related to Streptococcus pneumoniae
78. Streptococcus pneumoniae: Virulence factors, pathogenesis, and vaccines
79. Comparative efficacy of autolysin and pneumolysin as immunogens protecting mice against infection by Streptococcus pneumoniae
80. PspA, a protection-eliciting pneumococcal protein: Immunogenicity in isolated native PspA in mice
81. Cloning and nucleotide sequence analysis of PsaA, the Streptococcus pneumoniae gene encoding a 37-kilodalton protein homologous to previously reported Streptococcus sp. adhesions
82. Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein
83. Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2
84. Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae
85. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae
86. Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface protein adhesin A (PsaA)
87. Overview of DNA vaccines
88. Introduction: Nucleic acid vaccines
89. Immunization with DNA
90. Immunological properties of bacterial DNA
91. Immunologic epitope, gene, and immunity involved in pneumococcal glycoconjugate
92. Protective immunity and gene expression related to pneumococcal glycoconjugate
93. Maternal immunity and antibody response of neonatal mice to pneumococcal type 19F polysaccharide
94. Serum, breast milk, and infant antibody after maternal immunization with pneumococcal vaccine
95. Maternal immunization for the prevention of infections in late pregnancy and early infancy